These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

396 related items for PubMed ID: 19348656

  • 1. Effects of etanercept on urine neopterin levels in patients with psoriasis in a controlled, open-label study.
    Koc E, Tunca M, Akgul EO, Akar A, Kurt Y, Kurumlu Z, Erbil K, Kilic S.
    J Dermatol; 2009 Apr; 36(4):191-6. PubMed ID: 19348656
    [Abstract] [Full Text] [Related]

  • 2. Effects of etanercept on C-reactive protein levels in psoriasis and psoriatic arthritis.
    Strober B, Teller C, Yamauchi P, Miller JL, Hooper M, Yang YC, Dann F.
    Br J Dermatol; 2008 Aug; 159(2):322-30. PubMed ID: 18503600
    [Abstract] [Full Text] [Related]

  • 3. [Analysis of lymphocyte populations in psoriatic plaques following inhibition of tumor necrosis factor alpha with etanercept].
    Mahiques L, Pitarch G, Sánchez-Carazo JL, Pérez-Ferriols A, Soriano CJ, Alegre V.
    Actas Dermosifiliogr; 2007 Oct; 98(8):539-44. PubMed ID: 17919428
    [Abstract] [Full Text] [Related]

  • 4. Etanercept, a TNF antagonist for treatment for psoriatic arthritis and psoriasis.
    Mease PJ.
    Skin Therapy Lett; 2003 Jan; 8(1):1-4. PubMed ID: 12728284
    [Abstract] [Full Text] [Related]

  • 5. Etanercept treatment for children and adolescents with plaque psoriasis.
    Paller AS, Siegfried EC, Langley RG, Gottlieb AB, Pariser D, Landells I, Hebert AA, Eichenfield LF, Patel V, Creamer K, Jahreis A, Etanercept Pediatric Psoriasis Study Group.
    N Engl J Med; 2008 Jan 17; 358(3):241-51. PubMed ID: 18199863
    [Abstract] [Full Text] [Related]

  • 6. Efficacy and safety of etanercept in psoriasis after switching from other treatments: an observational study.
    Mazzotta A, Esposito M, Costanzo A, Chimenti S.
    Am J Clin Dermatol; 2009 Jan 17; 10(5):319-24. PubMed ID: 19658444
    [Abstract] [Full Text] [Related]

  • 7. The role of inflammatory markers in assessing disease severity and response to treatment in patients with psoriasis treated with etanercept.
    Kanelleas A, Liapi C, Katoulis A, Stavropoulos P, Avgerinou G, Georgala S, Economopoulos T, Stavrianeas NG, Katsambas A.
    Clin Exp Dermatol; 2011 Dec 17; 36(8):845-50. PubMed ID: 21790728
    [Abstract] [Full Text] [Related]

  • 8. Treatment of erythrodermic psoriasis with etanercept.
    Esposito M, Mazzotta A, de Felice C, Papoutsaki M, Chimenti S.
    Br J Dermatol; 2006 Jul 17; 155(1):156-9. PubMed ID: 16792768
    [Abstract] [Full Text] [Related]

  • 9. [Clinical experience with etanercept in the treatment of psoriasis].
    Martín B, Sánchez-Carazo JL, Pérez-Ferriols A, Laguna C, Oliver V, Alegre V.
    Actas Dermosifiliogr; 2008 Sep 17; 99(7):540-5. PubMed ID: 18682167
    [Abstract] [Full Text] [Related]

  • 10. [Long-term safety and efficacy of etanercept in the treatment of psoriasis].
    Zaragoza V, Pérez A, Sánchez JL, Oliver V, Martínez L, Alegre V.
    Actas Dermosifiliogr; 2010 Sep 17; 101(1):47-53. PubMed ID: 20109392
    [Abstract] [Full Text] [Related]

  • 11. Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis.
    Tyring S, Gordon KB, Poulin Y, Langley RG, Gottlieb AB, Dunn M, Jahreis A.
    Arch Dermatol; 2007 Jun 17; 143(6):719-26. PubMed ID: 17576937
    [Abstract] [Full Text] [Related]

  • 12. Initial experience with routine administration of etanercept in psoriasis.
    de Groot M, Appelman M, Spuls PI, de Rie MA, Bos JD.
    Br J Dermatol; 2006 Oct 17; 155(4):808-14. PubMed ID: 16965432
    [Abstract] [Full Text] [Related]

  • 13. Two years of experience with etanercept in recalcitrant psoriasis.
    Ahmad K, Rogers S.
    Br J Dermatol; 2007 May 17; 156(5):1010-4. PubMed ID: 17408393
    [Abstract] [Full Text] [Related]

  • 14. CTACK /CCL27 expression in psoriatic skin and its modification after administration of etanercept.
    Campanati A, Goteri G, Simonetti O, Ganzetti G, Giuliodori K, Stramazzotti D, Morichetti D, Bernardini ML, Mannello B, Fabris G, Offidani A.
    Br J Dermatol; 2007 Dec 17; 157(6):1155-60. PubMed ID: 17916208
    [Abstract] [Full Text] [Related]

  • 15. Efficacy of etanercept in an integrated multistudy database of patients with psoriasis.
    Gordon K, Korman N, Frankel E, Wang H, Jahreis A, Zitnik R, Chang T.
    J Am Acad Dermatol; 2006 Mar 17; 54(3 Suppl 2):S101-11. PubMed ID: 16488320
    [Abstract] [Full Text] [Related]

  • 16. Anti-tumour necrosis factor-alpha therapy increases body weight in patients with chronic plaque psoriasis: a retrospective cohort study.
    Gisondi P, Cotena C, Tessari G, Girolomoni G.
    J Eur Acad Dermatol Venereol; 2008 Mar 17; 22(3):341-4. PubMed ID: 18005022
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Patients with psoriasis respond to continuous open-label etanercept treatment after initial incomplete response in a randomized, placebo-controlled trial.
    Krueger GG, Elewski B, Papp K, Wang A, Zitnik R, Jahreis A.
    J Am Acad Dermatol; 2006 Mar 17; 54(3 Suppl 2):S112-9. PubMed ID: 16488321
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.